Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

NCT07553390 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells
DRUG: Trastuzumab deruxtecan (T-DXd)
DRUG: Rimiducid

Sponsor

M.D. Anderson Cancer Center